GTCM
TVTX icon

Gyon Technologies Capital Management’s Travere Therapeutics TVTX Stock Holding History

Gyon Technologies Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-38,162
Closed -$803K – 389
2022
Q4 		$803K Buy
38,162
+25,684
+206% +$544K 0.3% 108
2022
Q3 		$307K Sell
12,478
-10,961
-47% -$283K 0.1% 274
2022
Q2 		$568K Buy
23,439
+6,320
+37% +$159K 0.16% 154
2022
Q1 		$441K Sell
17,119
-95,459
-85% -$2.53M 0.31% 117
2021
Q4 		$3.49M Buy
112,578
+32,303
+40% +$910K 0.64% 27
2021
Q3 		$1.95M Buy
+80,275
New +$1.47M 0.52% 61

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Gyon Technologies Capital Management's TVTX Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2023, closing a stake of 38,162 shares — an estimated $803K sold.

Gyon Technologies Capital Management first reported a position in TVTX in Q3 2021 and held it in 6 quarters. The position peaked at $3.49M in Q4 2021. 174 funds tracked by Wall St. Rank hold TVTX as of Q1 2023.

  • Gyon Technologies Capital Management reported no remaining Travere Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 38,162 Travere Therapeutics shares in Q1 2023, an estimated $803K.
  • Gyon Technologies Capital Management first reported a position in Travere Therapeutics in Q3 2021 and held it in 6 quarters.
  • Gyon Technologies Capital Management's Travere Therapeutics position peaked at $3.49M in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.